April 29, 2025
Dr. Jingfang Ju's presented data at the 2025 annual meeting of the American Association for Cancer Research, which demonstrated that a modified microRNA, 5-FU-miR-15a, is well tolerated and led to stable disease in patients with acute myeloid leukemia. This opens the potential for the development of more effective ways to treat this disease, as highlighted this week in Blood Cancers Today (MicroRNA-Based Therapy Shows Promising Molecular Activity in AML | Blood Cancers Today).
